ProfoundBio’s Post

Just In: The Breast Cancer Drug Market In 2023, sales of leading breast cancer drugs reached approximately $28 billion. The primary agents driving this growth were CDK4/6 inhibitors and HER2-targeted therapies. For a deeper dive into emerging treatments & market trends, explore this latest analysis 👉 https://lnkd.in/dU-sKFqe @NatRevDrugDisc #bcsm #trendings

Early #diagnostic of #pancreaticcancer : 2 important announces this week from Immunovia AB and City of Hope Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study https://lnkd.in/gm_ncUNy An Exosome-based Liquid Biopsy Shows Promise for Early Detection of Pancreatic Cancer https://lnkd.in/dj5CZUB6 However, predictive diagnostics developed by ACOBIOM are needed to target 1st line therapies (#gemcitabine, #FOLFIRINOX). For more information: https://lnkd.in/gFGE6-AW

Watch our webinar with Amplia Therapeutics Limited, featuring CEO and MD Chris Burns. The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask Chris any questions about ATX that you may have. Key topics: - Data from recent trial - Why ovarian and pancreatic cancer? - What are the next key milestones and value drivers? - Where were the drugs discovered? Register here: https://hubs.la/Q02zctXZ0

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/eGZxBuKq

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/et-TjGuZ

Molecules of the Month – September 2024 | https://lnkd.in/gjAbvjaF September’s Molecules of the Month include Genentech's HPK1 inhibitor for cancer immunotherapy and Novo Nordisk's CB1 receptor inverse agonist for metabolic disorders. We also feature TAK-861, Takeda's highly selective OX2R agonist, which has entered a pivotal Ph. III trial, and Boehringer Ingelheim's pan-KRAS heterobifunctional degrader. Read the full article to find out what compounds made our September 2024 Molecules of the Month list, and check out recent articles for each. Full Article: https://lnkd.in/gjAbvjaF

We’re thrilled to announce that #preclinicaldata highlighting the differentiating properties of MYTX-011, our investigational cMET-targeting #ADC, has been published in the latest issue of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. Learn more: https://lnkd.in/ezrt85xm.   Discover how MYTX-011 has the potential to benefit a broader set of patients by offering increased on-target potency, enhanced tolerability, a longer half-life and higher efficacy when compared to other ADCs. Read the full article here: https://lnkd.in/eM44ZFH4.  

Dive into the world of antibody-drug conjugates with Sino Biological, Inc.! Discover how these innovative therapeutics target cancer cells with precision, sparing healthy tissues from harm. Read their latest article to learn more about the latest advancements in cancer treatment! >>> https://hubs.ly/Q02qHYlG0

Check out our latest article with BioTechniques!

Find out more in the September issue of Cancer Discovery! AACR Journals